CELL-BASED ASSAY DEVELOPMENT

Fluofarma is at first a cell biology company. When we engage in the development of a new cell-based assay, our prime focus is on the design of a relevant and predictive cellular model. We aim at testing compounds in in vitro models that closely mimic in vivo conditions. Our second priority is to optimize assays for automated high-content screening, enabling robust and quantitative data analysis at the single cell level.

CUSTOMIZED CELLULAR MODELS

Starting from the pathophysiological context you’re interested in, we custom-design an in vitro cellular model in 96-/384-well format for high-throughput cell-based screening.

RELEVANT PHENOTYPIC & MOLECULAR READOUTS

We hold more than 10-year-experience in assay development across a wide range of drug targets, functional responses, intracellular localizations, upstream or downstream activation markers.In each case, we select the most relevant and robust readout to highlight the specific action of compounds.For better compound profiling, and to reduce turnaround time, we favor multiplexed readouts.

ASSAY MINIATURIZATION AND AUTOMATION

We optimize assays to generate robust and quantitative data at high-throughput, while minimizing compound and reagent consumption. Assays are miniaturized, multiplexed and adapted to a relevant platform, for automated signal analysis: